-
MicuRx Pharmaceuticals Doses First Patient in China for MRX-8 Trial
•
Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the first patient dosing in a Phase I clinical study in China for its MRX-8, a new drug against gram-negative drug-resistant bacteria. This marks a significant milestone in the development of MRX-8, which aims to address the growing challenge of…
-
Zhifei Bio Initiates Global Study for Omicron-Delta COVID-19 Vaccine in Uzbekistan
•
China-based Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd has announced the initiation of a global clinical study for its Omicron-Delta variant recombinant COVID-19 protein vaccine in Uzbekistan. This marks a significant step in the development of the second-generation vaccine, which targets the Omicron and Delta variants. Previous Clinical StudiesPreviously, Zhifei Bio chose…
-
Mainline Biosciences Raises RMB 100M in Series A Financing for Peptide Drugs
•
Mainline Biosciences, a polypeptide drug developer based in Zhongshan, has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A financing round. The round was led by Fuho Capital, with participation from Techsnow Capital and Dingfu Investment. The proceeds will be used to construct the company’s…
-
Jiangsu Trausim Raises RMB 100M in Series A Financing for Dental Implants
•
China-based Jiangsu Trausim Medical Instrument Co., Ltd, a wholly-owned subsidiary of Fulong Holdings and focused on dental implants and surgical instruments, has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A financing round. The round was led by Sunho Capital and MF Capital, with participation…
-
Cyramza Prescribed in China for Advanced Gastric Cancer
•
Cyramza (ramucirumab) was first prescribed on November 6, 2022, at the Zhongshan Hospital in Shanghai and Beijing Cancer Hospital, marking a new treatment option for second-line advanced gastric cancer patients in China. This milestone follows the drug’s market approval in March 2022 for treating second-line advanced metastatic gastric cancer in…
-
Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization
•
German pharmaceutical giant Merck KGaA (ETR: MRK) has announced a collaboration with Biotheus, a China-based biotech company focused on developing treatments for cancer and autoimmune diseases. The partnership aims to streamline Biotheus’ development process by utilizing Merck’s Blazar Rodent Panel, which significantly reduces the turn-around-time (TAT) of cell line characterization…
-
Merck’s Keytruda Receives 10th Indication Approval in China for TNBC
•
US-based Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab) has obtained its 10th indication approval from China’s National Medical Products Administration (NMPA). The drug can now be used to treat early high-risk triple negative breast cancer (TNBC) with tumors expressing PD-L1 (CPS ≥ 20) in…
-
Takeda Partners with CCCMHPIE to Boost Rare Disease Drug Access in China
•
The 5th China International Import Expo (CIIE) saw Japan-based Takeda Pharmaceutical Co., Ltd’s China unit announce a partnership with the China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE). The collaboration aims to enhance professional collaborations in the rare disease field. Financial details of the…
-
Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies
•
Xellsmart, a stem-cell startup based in Suzhou, has reportedly raised over RMB 200 million (USD 27.6 million) in a Series A1 financing round. The round was co-led by Qiming Venture Partners, Lilly Asia Ventures, Xiamen Jinyuan Zhanhong Investment, and China-Singapore Suzhou Industrial Park Development Group. Other investors included Oriza Holdings,…
-
Novo Nordisk Reports 16% YOY Growth in Q3, Raises Full-Year Guidance
•
Denmark-based biopharma Novo Nordisk A/S (NYSE: NVO) has released its Q3 2022 earnings report. The company reported a 16% year-on-year (YOY) growth in constant exchange rates (CER) to DKK 128.9 billion (USD 17.3 billion) over the 9-month period. Sales for the three-month Q3 period were up 15% (CER) to DKK…
-
Novo Nordisk Partners with Shanghai Pharma for Smart Logistics at CIIE
•
Novo Nordisk (NYSE: NVO) has announced a strategic partnership with China’s Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) unveiled at the 5th China International Import Expo (CIIE). The Denmark-based major will be provided with smart and modern logistics warehouses, enabling intensive, standardized, information-based, and intelligent drug logistics management and operation for…
-
SIMR Biotechnology Raises RMB 150M in Series C1 Financing Round
•
China’s Shanghai SIMR Biotechnology Co., Ltd has reportedly raised RMB 150 million (USD 20.7 million) in a Series C1 financing round, alongside “tens of millions” in bank loans. Investors included Guanzi Private Fund Management, Tian Rui Feng Nian, and Yixing Huarui. The proceeds will be used to support pre-clinical development,…
-
PingAn Good Doctor Partners with Roche and OrigiMed at CIIE
•
The 5th China International Import Expo (CIIE) saw China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor, announce partnerships with Swiss giant Roche and its compatriot firm OrigiMed, a precision medicine company. The collaboration aims to expand the pan-solid tumor payment service mode,…
-
Organon Partners with Alibaba Health to Enhance Chronic Disease Management
•
Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK) in mid-2021, has announced another strategic deal at the 5th China International Import Expo (CIIE). This time, Organon is partnering with Alibaba Health Information Technology Ltd…
-
Qilu Pharma’s QL1706 Shows Promise in Phase II Cervical Cancer Study
•
China-based Qilu Pharmaceutical has published the latest results from a Phase II clinical study for QL1706, a dual-targeted antibody against programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). The findings were presented at the Chinese Society of Clinical Oncology (CSCO) annual meeting. Study Design and ResultsPrevious clinical studies…
-
Organon Sponsors Retail Pharmacy Health Center at CIIE
•
The 5th China International Import Expo (CIIE) saw Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK) in mid-2021, sponsor the Retail Pharmacy Health Center of Excellence. This program is hosted by the China Association…
-
Sanofi Partners with China Resources Sanjiu at CIIE for Consumer Healthcare
•
The 5th China International Import Expo (CIIE) saw Sanofi’s consumer healthcare unit announce a partnership with China Resources Sanjiu Medical & Pharmaceutical Co., Ltd (SHE: 000999). This collaboration marks a significant milestone in the companies’ ongoing efforts to enhance consumer healthcare in China. Partnership History and RenewalThe two companies first…
-
Sumitomo Dainippon Partners with Profex to Promote Antipsychotics in China
•
Japan-based Sumitomo Dainippon Pharma Co., Ltd has announced a partnership with Profex, a trade company in Shanghai. The collaboration aims to promote Lonasen (blonanserin) and Latuda (lurasidone), both antipsychotic medications, in the Chinese market. Financial details of the partnership were not disclosed. Epidemiological ContextAccording to the latest epidemiological survey in…
-
Eli Lilly Partners with AmoyDx and Burning Rock for Retevmo Companion Diagnostics
•
The 5th China International Import Expo (CIIE) saw US-based Eli Lilly (NYSE: LLY) announce a partnership with China-based Amoy Diagnostics Co., Ltd (AmoyDx) and Burning Rock Biotech Ltd (NASDAQ: BNR). The collaboration aims to enhance the development of companion diagnostics (CDx) for Retevmo (selpercatinib), the world’s first highly-selective RET kinase…
-
BioNTech’s Comirnaty Gets Limited Authorization in China Amid Scholz Visit
•
Germany-based mRNA specialist BioNTech (NASDAQ: BNTX) reportedly benefited from German Chancellor Olaf Scholz’s visit to China this week. Chinese authorities agreed to a limited authorization for the mRNA-based COVID-19 vaccine Comirnaty (BNT162b2) to be used by German national expatriates living in China, according to media sources including Bloomberg, quoting Scholz.…
